KREMEN1 and Alzheimer disease: The neuroprotective effects of SNHG1 knock-down on Aβ-induced phenomena were attenuated by miR-137 inhibitors or by overexpression of KREMEN1 (Kringle-Containing Transmembrane Protein 1), a direct target of miR-137-3p that functions as a Wnt antagonist, and was shown to contribute to synapse loss in a cortico-hippocampal transgenic murine cell culture model of AD [48,57].